Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IGBA Supergroup Gets Audience With WTO

CEO Advisory Committee Outlines ‘Essential Role’ Of Generics And Biosimilars

Executive Summary

The CEO advisory committee established by the IGBA has held its inaugural meeting and begun discussions with the director-general of the World Trade Organization to promote the “essential role” of generics and biosimilars in global health, with the interaction described as a first step towards a continuing dialog.

You may also be interested in...



Lupin’s Gupta Moves Up To Lead IGBA Leadership Committee

Lupin CEO Vinita Gupta will next year take over from Sandoz chief executive Richard Saynor as chair of the IGBA’s CEO advisory committee, representing the voice of the global off-patent industry. At the same time, Insud CEO Lucas Sigman will take over from Gupta as vice-chair.

IGBA Leaders Open Up Talks With WIPO

The IGBA’s CEO advisory committee of top off-patent industry leaders has met with Daren Tang, director general of the WIPO, to discuss the importance of a balanced global intellectual property regime.

Jonathan Kimball Named IGBA Chair For 2023

The IGBA chair passes to Jonathan Kimball. He will head the global off-patent industry organization as it steps up its activities in global policy.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel